Innate Pharma Reports 2025 Financials and Clinical Trial Updates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IPHA?
Source: Newsfilter
- Clinical Trial Progress: Innate Pharma plans to initiate the confirmatory Phase 3 TELLOMAK-3 trial for Lacutamab in H2 2026, contingent on ongoing negotiations for non-dilutive financing options, indicating the company's commitment to addressing unmet needs in cutaneous T-cell lymphoma.
- Financial Overview: As of December 31, 2025, Innate Pharma reported cash and cash equivalents of €44.8 million, a significant drop from €91.1 million in 2024, with an anticipated cash runway extending until Q3 2026, highlighting financial management challenges.
- Revenue Decline: The company generated €9.0 million in revenue for 2025, down 55.2% from €20.1 million in 2024, primarily due to a sharp decrease in collaboration and licensing income from AstraZeneca and Sanofi, reflecting challenges in its commercialization efforts.
- R&D Spending Adjustments: Research and development expenses totaled €43.6 million in 2025, a 16.1% decrease from €52.0 million in 2024, indicating cost control measures that may impact future clinical progress and competitive positioning.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IPHA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IPHA
Wall Street analysts forecast IPHA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.260
Low
5.00
Averages
6.50
High
8.00
Current: 1.260
Low
5.00
Averages
6.50
High
8.00
About IPHA
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Innate Pharma Reports 2025 Financials and Clinical Trial Updates
- Clinical Trial Progress: Innate Pharma plans to initiate the confirmatory Phase 3 TELLOMAK-3 trial for Lacutamab in H2 2026, contingent on ongoing negotiations for non-dilutive financing options, indicating the company's commitment to addressing unmet needs in cutaneous T-cell lymphoma.
- Financial Overview: As of December 31, 2025, Innate Pharma reported cash and cash equivalents of €44.8 million, a significant drop from €91.1 million in 2024, with an anticipated cash runway extending until Q3 2026, highlighting financial management challenges.
- Revenue Decline: The company generated €9.0 million in revenue for 2025, down 55.2% from €20.1 million in 2024, primarily due to a sharp decrease in collaboration and licensing income from AstraZeneca and Sanofi, reflecting challenges in its commercialization efforts.
- R&D Spending Adjustments: Research and development expenses totaled €43.6 million in 2025, a 16.1% decrease from €52.0 million in 2024, indicating cost control measures that may impact future clinical progress and competitive positioning.
See More
Innate Pharma to Host Financial Results Conference Call
- Conference Call Announcement: Innate Pharma will hold a conference call on March 26, 2026, at 2 p.m. CET / 9 a.m. EDT to discuss its financial results for the year ending December 31, 2025, which is expected to attract significant investor and analyst interest.
- Executive Participation: The call will feature key executives, including CEO Jonathan Dickinson and CFO Frédéric Lombard, highlighting the leadership's commitment to financial transparency and aiming to bolster investor confidence.
- Webcast Details: The event will be available via live webcast, with participants able to access it through the provided link, and a replay will be available on the company’s website for 90 days, ensuring that those unable to attend live can still access the information.
- Company Overview: Innate Pharma is a global clinical-stage biotechnology company focused on developing cancer immunotherapies, advancing a portfolio of differentiated potential first and/or best-in-class assets, which underscores the company's strategic positioning in addressing high unmet medical needs.
See More
Innate Pharma to Participate in 2026 Healthcare Conference
- Conference Participation: Innate Pharma will participate in the Leerink Partners Global Healthcare Conference from March 8-11, 2026, in Miami, Florida, showcasing its latest advancements in cancer immunotherapy.
- Executive Engagement: The company's executives will engage in a fireside chat on March 9 at 3:40 PM ET and hold one-on-one meetings, aiming to deepen investor relations and enhance market confidence.
- Innovative Product Portfolio: Innate Pharma is developing several potential first-in-class or best-in-class therapeutics, including Nectin-4 ADC and anti-KIR3DL2 antibodies, focusing on areas of high unmet medical need, demonstrating its innovative capabilities in biotechnology.
- Strategic Collaborations: The company has established partnerships with leading biopharmaceutical firms like Sanofi and AstraZeneca to advance innovation in immuno-oncology, further solidifying its competitive position in the global market.
See More
Innate Pharma to Participate in Global Healthcare Conference
- Conference Participation: Innate Pharma will participate in the Leerink Partners Global Healthcare Conference from March 8-11, 2026, in Miami, where its executives will engage in a fireside chat and one-on-one meetings to enhance the company's visibility among investors.
- Fireside Chat Timing: The fireside chat is scheduled for March 9, 2026, at 3:40 PM ET, which is expected to attract attention and showcase the company's latest advancements and future strategies in cancer immunotherapy.
- Innovative Product Portfolio: Innate Pharma is developing a range of potential first and/or best-in-class therapeutics, including IPH4502, lacutamab, and monalizumab, focusing on areas of high unmet medical need, demonstrating the company's strong R&D capabilities in biotechnology.
- Strategic Partnerships: The company has established collaborations with leading biopharmaceutical firms such as Sanofi and AstraZeneca, aiming to drive innovation in immuno-oncology and further solidify its competitive position in the global market.
See More
Innate Pharma Reports Share and Voting Rights Data for 2025
- Total Shares Disclosure: As of December 31, 2025, Innate Pharma reports a total of 93,719,323 ordinary shares, along with 6,324 preferred shares from 2016 and 7,581 from 2017, indicating stability in its capital structure.
- Voting Rights Information: The company has a total of 94,484,443 theoretical voting rights and 94,465,868 exercisable voting rights, ensuring transparency regarding shareholder rights, which helps maintain investor confidence.
- Compliance Adherence: This disclosure aligns with the French Commercial Code and AMF regulations, demonstrating Innate Pharma's commitment to compliance, which enhances its credibility among investors.
- Market Transparency Enhancement: By regularly releasing share and voting rights data, Innate Pharma improves market transparency, facilitating investor understanding of its governance structure, potentially attracting more investor interest.
See More
Innate Pharma Releases Share and Voting Rights Data as of December 18, 2025
- Total Shares Disclosure: As of December 18, 2025, Innate Pharma has 92,197,823 ordinary shares outstanding, indicating stability in its capital structure, which may enhance investor confidence.
- Preferred Shares Information: The company also holds 6,324 Preferred Shares from 2016 and 7,581 from 2017, reflecting its capital diversity that could attract various types of investors.
- Voting Rights Overview: The total theoretical voting rights stand at 92,962,943, with exercisable rights at 92,944,368, showcasing transparency in corporate governance that may boost shareholder engagement.
- Biotech Development Focus: Innate Pharma is dedicated to developing immunotherapies for cancer, advancing multiple potential first-in-class assets, demonstrating its strategic positioning in high unmet medical needs in the healthcare sector.
See More
Innate Pharma Reports 2025 Financials and Clinical Trial Updates
- Clinical Trial Progress: Innate Pharma plans to initiate the confirmatory Phase 3 TELLOMAK-3 trial for Lacutamab in H2 2026, contingent on ongoing negotiations for non-dilutive financing options, indicating the company's commitment to addressing unmet needs in cutaneous T-cell lymphoma.
- Financial Overview: As of December 31, 2025, Innate Pharma reported cash and cash equivalents of €44.8 million, a significant drop from €91.1 million in 2024, with an anticipated cash runway extending until Q3 2026, highlighting financial management challenges.
- Revenue Decline: The company generated €9.0 million in revenue for 2025, down 55.2% from €20.1 million in 2024, primarily due to a sharp decrease in collaboration and licensing income from AstraZeneca and Sanofi, reflecting challenges in its commercialization efforts.
- R&D Spending Adjustments: Research and development expenses totaled €43.6 million in 2025, a 16.1% decrease from €52.0 million in 2024, indicating cost control measures that may impact future clinical progress and competitive positioning.
See More
Innate Pharma to Host Financial Results Conference Call
- Conference Call Announcement: Innate Pharma will hold a conference call on March 26, 2026, at 2 p.m. CET / 9 a.m. EDT to discuss its financial results for the year ending December 31, 2025, which is expected to attract significant investor and analyst interest.
- Executive Participation: The call will feature key executives, including CEO Jonathan Dickinson and CFO Frédéric Lombard, highlighting the leadership's commitment to financial transparency and aiming to bolster investor confidence.
- Webcast Details: The event will be available via live webcast, with participants able to access it through the provided link, and a replay will be available on the company’s website for 90 days, ensuring that those unable to attend live can still access the information.
- Company Overview: Innate Pharma is a global clinical-stage biotechnology company focused on developing cancer immunotherapies, advancing a portfolio of differentiated potential first and/or best-in-class assets, which underscores the company's strategic positioning in addressing high unmet medical needs.
See More
Innate Pharma to Participate in 2026 Healthcare Conference
- Conference Participation: Innate Pharma will participate in the Leerink Partners Global Healthcare Conference from March 8-11, 2026, in Miami, Florida, showcasing its latest advancements in cancer immunotherapy.
- Executive Engagement: The company's executives will engage in a fireside chat on March 9 at 3:40 PM ET and hold one-on-one meetings, aiming to deepen investor relations and enhance market confidence.
- Innovative Product Portfolio: Innate Pharma is developing several potential first-in-class or best-in-class therapeutics, including Nectin-4 ADC and anti-KIR3DL2 antibodies, focusing on areas of high unmet medical need, demonstrating its innovative capabilities in biotechnology.
- Strategic Collaborations: The company has established partnerships with leading biopharmaceutical firms like Sanofi and AstraZeneca to advance innovation in immuno-oncology, further solidifying its competitive position in the global market.
See More
Innate Pharma to Participate in Global Healthcare Conference
- Conference Participation: Innate Pharma will participate in the Leerink Partners Global Healthcare Conference from March 8-11, 2026, in Miami, where its executives will engage in a fireside chat and one-on-one meetings to enhance the company's visibility among investors.
- Fireside Chat Timing: The fireside chat is scheduled for March 9, 2026, at 3:40 PM ET, which is expected to attract attention and showcase the company's latest advancements and future strategies in cancer immunotherapy.
- Innovative Product Portfolio: Innate Pharma is developing a range of potential first and/or best-in-class therapeutics, including IPH4502, lacutamab, and monalizumab, focusing on areas of high unmet medical need, demonstrating the company's strong R&D capabilities in biotechnology.
- Strategic Partnerships: The company has established collaborations with leading biopharmaceutical firms such as Sanofi and AstraZeneca, aiming to drive innovation in immuno-oncology and further solidify its competitive position in the global market.
See More
Innate Pharma Reports Share and Voting Rights Data for 2025
- Total Shares Disclosure: As of December 31, 2025, Innate Pharma reports a total of 93,719,323 ordinary shares, along with 6,324 preferred shares from 2016 and 7,581 from 2017, indicating stability in its capital structure.
- Voting Rights Information: The company has a total of 94,484,443 theoretical voting rights and 94,465,868 exercisable voting rights, ensuring transparency regarding shareholder rights, which helps maintain investor confidence.
- Compliance Adherence: This disclosure aligns with the French Commercial Code and AMF regulations, demonstrating Innate Pharma's commitment to compliance, which enhances its credibility among investors.
- Market Transparency Enhancement: By regularly releasing share and voting rights data, Innate Pharma improves market transparency, facilitating investor understanding of its governance structure, potentially attracting more investor interest.
See More
Innate Pharma Releases Share and Voting Rights Data as of December 18, 2025
- Total Shares Disclosure: As of December 18, 2025, Innate Pharma has 92,197,823 ordinary shares outstanding, indicating stability in its capital structure, which may enhance investor confidence.
- Preferred Shares Information: The company also holds 6,324 Preferred Shares from 2016 and 7,581 from 2017, reflecting its capital diversity that could attract various types of investors.
- Voting Rights Overview: The total theoretical voting rights stand at 92,962,943, with exercisable rights at 92,944,368, showcasing transparency in corporate governance that may boost shareholder engagement.
- Biotech Development Focus: Innate Pharma is dedicated to developing immunotherapies for cancer, advancing multiple potential first-in-class assets, demonstrating its strategic positioning in high unmet medical needs in the healthcare sector.
See More
